PDGF/PDGFR: A Possible Molecular Target in Scleroderma Fibrosis

Chiara Paolini1, Silvia Agarbati1, Devis Benfaremo1,2

  • 1Department of Clinical and Molecular Sciences, Università Politecnica delle Marche, 60126 Ancona, Italy.

Insights

Systemic sclerosis (SSc) involves complex fibrosis. This review explores the PDGF/PDGFR pathway

Area of Science:

  • Connective tissue disorders
  • Immunology
  • Fibrosis research

Background:

  • Systemic sclerosis (SSc) is a heterogeneous connective tissue disease.
  • Pathogenesis involves vascular, immune, and fibrotic changes.
  • Current SSc therapies are limited and nonspecific.

Purpose of the Study:

  • To review the role of the PDGF/PDGFR pathway in SSc fibrosis.
  • To discuss the potential involvement of anti-PDGFRα autoantibodies in SSc.
  • To highlight emerging PDGF/PDGFR-targeting therapies for SSc.

Main Methods:

  • Literature review focusing on PDGF/PDGFR signaling in fibrosis.
  • Analysis of studies investigating anti-PDGFRα autoantibodies in SSc.
  • Compilation of data on PDGF/PDGFR-targeted therapeutic strategies.

Main Results:

  • The PDGF/PDGFR pathway is a key mediator of tissue fibrosis in SSc.
  • Stimulatory anti-PDGFRα autoantibodies may contribute to SSc pathogenesis.
  • Several PDGF/PDGFR-targeting therapies show promise for SSc treatment.

Conclusions:

  • Targeting the PDGF/PDGFR pathway offers a promising therapeutic avenue for SSc.
  • Further research into anti-PDGFRα autoantibodies could elucidate SSc mechanisms.
  • Developing specific PDGF/PDGFR inhibitors may lead to effective SSc treatments.